WuXi PharmaTech Begins Construction of New R&D and cGMP Manufacturing Campus in Changzhou

WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device research and development (R&D) services company with operations in China and the US, has announced that its manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co., Ltd, has begun construction of a new, fully integrated R&D and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai. The new construction aims to meet the rapidly growing demand for WuXi's manufacturing services, which have quadrupled their revenues in the past 4 years.

The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities. Facilities constructed in phase 1 will double the company's current manufacturing capacity and be operational by the fourth quarter of 2015. Upon completion of the entire project, the site will triple current capacity and can have more than 1500 employees, including chemists, production staff, and supporting staff, to seamlessly move new chemical entities from early stage process development through preclinical and clinical deliveries to commercial production.

"This project marks an important milestone in STA's mission of building a fully integrated API development and manufacturing platform," said Dr Ge Li, Chairman and CEO of WuXi PharmaTech. "It furthers our commitment to providing partners worldwide with highly efficient and cost-effective solutions that help bring better medicines faster to patients."